Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination by Braten, Ori et al.
Numerous proteins with unique characteristics are
degraded by the 26S proteasome
following monoubiquitination
Ori Bratena,1, Ido Livneha,1, Tamar Zivb,c, Arie Admonb,c, Izhak Kehatd, Lilac H. Caspid, Hedva Gonena,
Beatrice Bercovicha, Adam Godzike, Samad Jahandidehe, Lukasz Jaroszewskie, Thomas Sommerf, Yong Tae Kwong,h,
Mainak Guharoyi, Peter Tompai,j,k, and Aaron Ciechanovera,g,h,2
aTechnion Integrated Cancer Center, The Rappaport Faculty of Medicine and Research Institute, Technion–Israel Institute of Technology, Haifa, 3109602,
Israel; bSmoler Proteomic Center, Technion–Israel Institute of Technology, Haifa, 3200003, Israel; cFaculty of Biology, Technion–Israel Institute of
Technology, Haifa, 3200003, Israel; dDepartment of Physiology, The Rappaport Faculty of Medicine and Research Institute, Technion–Israel Institute of
Technology, Haifa, 3109602, Israel; eBioinformatics and Systems Biology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037;
fMax Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; gProtein Metabolism Medical Research Center, College of Medicine, Seoul National
University, Seoul 110-799, South Korea; hDepartment of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 110-799, South Korea;
iVlaams Instituut voor Biotechnologie Structural Biology Research Center, Vrije Universiteit Brussel, 1050 Brussels, Belgium; jStructural Biology Brussels, Vrije
Universiteit Brussel, 1050 Brussels, Belgium; and kInstitute of Enzymology, Research Center for Natural Sciences of the Hungarian Academy of Sciences,
1117 Budapest, Hungary
Contributed by Aaron Ciechanover, June 4, 2016 (sent for review March 21, 2016; reviewed by Yinon Ben-Neriah and Ivan Dikic)
The “canonical” proteasomal degradation signal is a substrate-
anchored polyubiquitin chain. However, a handful of proteins were
shown to be targeted following monoubiquitination. In this study,
we established—in both human and yeast cells—a systematic ap-
proach for the identification of monoubiquitination-dependent pro-
teasomal substrates. The cellular wild-type polymerizable ubiquitin
was replacedwith ubiquitin that cannot form chains. Using proteomic
analysis, we screened for substrates that are nevertheless degraded
under these conditions compared with those that are stabilized, and
therefore require polyubiquitination for their degradation. For randomly
sampled representative substrates, we confirmed that their cellular sta-
bility is in agreement with our screening prediction. Importantly, the
two groups display unique features: monoubiquitinated substrates are
smaller than the polyubiquitinated ones, are enriched in specific path-
ways, and, in humans, are structurally less disordered. We suggest that
monoubiquitination-dependent degradation is more widespread than
assumed previously, and plays key roles in various cellular processes.
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Polymers of ubiquitin (Ub) are formed on proteasomal substratesin eukaryotic cells by the concerted action of three enzymes: the
Ub-activating enzyme (E1), a Ub-carrier protein [E2; known also as
Ub-conjugating enzyme (UBC)], and a Ub ligase (E3), which is the
specific substrate-recognizing element of the system. The Ub chains
typically consist of multiple moieties linked to one another via an
isopeptide bond between the C-terminal Gly residue of the distal
moiety and the e-NH2 group of Lys48 of the proximal one (1).
In addition, the system can also catalyze modification by a
single Ub moiety (monoubiquitination) or multiple single Ub
moieties (multiple monoubiquitinations), each modifying a dis-
tinct lysine residue (2). Generally, monoubiquitination has been
conceived as a nondestructive signal. Furthermore, it has been
suggested that efficient proteasomal targeting requires a chain with
a minimal length of four Ub moieties (3). Monoubiquitination is
known to be involved in multiple biological processes. For example,
monoubiquitination of proteins containing a ubiquitin-binding do-
main (UBD) often mediates autoinhibition by a UBD–Ub inter-
action (4, 5). Signal transduction by membrane receptors, such as
the EGFR, is attenuated by monoubiquitination-mediated receptor
internalization (6). The subcellular localization of small GTPases is
controlled, among other posttranslational modifications, by mono-
ubiquitination (7, 8), and histone monoubiquitination regulates
nucleasomal structure, thus affecting gene expression (9). Emerging
reports indicate, however, that several substrates can be degraded
following monoubiquitination (10–13). Partial degradation/processing
of the p105 precursor of NF-κB, which results in release of the p50
active subunit of the transcription factor, is dependent on multiple
monoubiquitinations (14). Importantly, these findings demonstrate
that the proteasome can recognize a single Ub moiety (moieties) and
imply the existence of monoubiquitination vs. polyubiquitination
“decision” mechanisms. In this context, a previous study has sug-
gested that the chain length required for proteasomal degradation is
determined by the size of the substrate, and possibly other charac-
teristics that affect the affinity of the modified substrate to the pro-
teasome. Specifically, it was suggested that substrates smaller than
150 aa are degraded following monoubiquitination, whereas longer
substrates require longer chains. Thus, a dynamic model was pro-
posed, according to which the chain elongates to a point where the
affinity to the proteasome is high enough to secure a stable binding
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of the conjugated substrate, its concomitant detachment from the
E3, and its subsequent degradation (15). Another study demonstrated
that restricting the number of ubiquitinatable Lys residues can switch
the mode of modification necessary for degradation from multiple
monoubiquitinations to polyubiquitination, suggesting that, in the cell,
the masking of Lys residues by protein–protein interactions or post-
translational modifications can affect the mode of ubiquitination (11).
However, all of these studies have been carried out using
specific substrates. Therefore, general conclusions regarding
monoubiquitination-dependent degradation mechanisms, the
population of substrates that are degraded following this modi-
fication, and importantly, whether they have common distinct
characteristics, have remained limited.
In this study, we used a systematic proteomic approach for the
identification and characterization of monoubiquitination-dependent
proteasomal substrates. By silencing the endogenous WT Ub fol-
lowed by expression of nonpolymerizable lysineless Ub, we identified
numerous substrates in both mammalian and yeast cells that are
targeted by the proteasome following monoubiquitination or mul-
tiple monoubiquitinations. Interestingly, we confirmed a previous
hypothesis (15) that there is a correlation between the length of the
substrate and its requirement for either monoubiquitination or pol-
yubiquitination. Also, the monoubiquitinated substrates are enriched
in specific pathways [e.g., oxidative stress, carbohydrate transport,
and components of the ubiquitin–proteasome system (UPS) itself]
and, in humans, are structurally less disordered.
Results
Establishing a System for Induction of Monoubiquitination in Cells. In gen-
eral, to model monoubiquitination (or multiple monoubiquitinations),
we silenced endogenous Ub expression and replaced it with a lysineless
Ub (UbK0). This nonpolymerizable Ub species, in which all seven Lys
residues were replaced with Arg, can modify each Lys in the target
substrate only once and cannot be further ubiquitinated (16–19).
To study monoubiquitination in yeast, we used a modification
of a previously described Ub replacement method (20). Briefly,
all of the Ub-coding genes were deleted and replaced by galactose-
inducible Ub (ΔUb strain), and either copper-inducible UbWT or
UbK0 (ΔUbUbWT or ΔUbUbK0, respectively). Thus, Ub expression
can be silenced by adding glucose, and Ub reexpression can be
induced by adding copper to the growth medium (Fig. 1A). To
validate Ub silencing and reexpression, ΔUb, ΔUbUbWT, and
ΔUbUbK0 yeast strains were treated with glucose and copper. As
shown in Fig. 1B, Ub expression was efficiently suppressed, and
both UbWT and UbK0 were markedly expressed.
To assess monoubiquitination in human cells, we used a modi-
fication of a previously described Ub replacement model in human
cultured cells (21). Briefly, endogenous Ub is silenced in U2OS
cells by a Ub-specific tetracycline-induced shRNA (shUb), and
either HA-UbWT or HA-UbK0 is expressed following infection with
an adenoviral vector (Fig. 1A). To evaluate Ub silencing efficiency,
we monitored Ub and Ub conjugates level in U2OSshUb cells fol-
lowing tetracycline treatment. As demonstrated in Fig. 1Ci, the
level of both Ub and Ub–protein conjugates were significantly
decreased. In the endogenous Ub-silenced cells, both HA-UbWT and
HA-UbK0 were efficiently expressed and assembled into high–
molecular-mass conjugates following adenoviral expression (Fig.
1Cii). It should be noted that the pattern of conjugation appears
similar for both UbWT and UbK0 expression. This is probably due
to the numerous substrates with a broad range of molecular mass
that are conjugated, and from the possibility that many of them
are modified by multiple monoubiquitinations.
To demonstrate Ub replacement using an additional method,
we quantified Ub using mass spectrometry (MS). As shown in Fig.
S1A, tryptic digestion of UbWT and UbK0 yields both common
and differential MS-detectable peptides. To assess Ub replacement
in yeast, we treated ΔUbUbK0 cells with glucose and copper, and
quantified Ub-derived peptides by MS. As illustrated in Fig. S1B,
UbK0 was markedly more abundant than endogenous Ub. To
evaluate UbK0 expression in human cells, we overexpressed HA-
UbK0 via adenoviral infection using increasing multiplicities of in-
fection (MOIs). As displayed in Fig. S1C, UbK0 expression level
was MOI dependent and significantly exceeded the level of
endogenous Ub.
Taken together, these data demonstrate the effectiveness of
our Ub replacement strategies and suggest that our experimental
systems are suitable for studying protein monoubiquitination.
Systematic Identification of Monoubiquitination-Dependent Proteasome
Substrates. To identify substrates that are degraded following mono-
ubiquitination, we replaced Ub with either UbK0 or UbWT (as a con-
trol). We then used anti–K-e-GG immunoprecipitation (Fig. S2) to
enrich and quantify by MS GlyGly-modified peptides derived from
tryptic digestion of ubiquitinated proteins (Fig. S2). This method
enabled us also to identify ubiquitination sites (Ubsites). To verify
that the ubiquitinated proteins serve indeed as proteolytic substrates,
we monitored also the level of nonmodified peptides derived from
them (Fig. 2A). To ascertain reproducibility, we performed several
independent biological replicates for each model organism, using
both stable isotope labeling by amino acids in cell culture (SILAC)
and label-free quantification (Table S1). As shown in Fig. 2B, iden-
tification of the proteins was quite reproducible. Similar to pre-
vious data (22), identification of Ubsites within proteins was less
reproducible.
This established experimental setup enabled us to discriminate be-
tween proteins degraded following modification by monoubiquitination
(or multiple monoubiquitination), and those that are degraded
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Fig. 1. Replacement of endogenous Ub by UbK0 in yeast and mammalian cells.
(A) Workflow describing Ub silencing and reexpression (see a detailed de-
scription under Experimental Procedures). (B) Ub replacement in yeast cells.
ΔUb, ΔUbUbWT, and ΔUbUbK0 yeast cells were treated for Ub silencing and Ub
reexpression as indicated. Yeast cells were analyzed by trichloroacetic acid (TCA)
lysis followed by SDS/PAGE and Western blotting (WB) using the indicated
antibodies. (C) Ub replacement in human cells. (i) Ub silencing. To silence Ub,
U2OSshUb cells were treated with tetracycline (1 μg/mL) for the indicated times.
(ii) Ub reexpression. Following Ub silencing, cells were infected with viral vec-
tors expressing UbWT or UbK0. In both panels, lysates were analyzed via SDS/
PAGE followed by WB using the indicated antibodies.
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only following polyubiquitination. We calculated the MS signal
intensity ratios following either UbK0 or UbWT expression for
both proteins and immunoprecipitated ubiquitinated sites
(denoted “protein K0/WT intensity ratio” and “site K0/WT in-
tensity ratio,” respectively; see Dataset S1 for raw data). As illus-
trated in Fig. 2C and based on K0/WT intensity ratios, we classified
ubiquitinated proteins to putative monoubiquitination- and poly-
ubiquitination-dependent proteasome substrates as follows.
Monoubiquitination-dependent proteasomal substrates are
expected to be unaffected by UbK0 expression. Alternatively, as
UbK0 expression renders proteasomes less occupied by poly-
ubiquitination-dependent substrates, increased proteasome avail-
ability may result in accelerated degradation of monoubiquitination-
dependent substrates. Thus, we required these substrates to (i) have
a site K0/WT ratio <1; (ii) have a detectable MS signal in at least
two independent experiments; and (iii) have a protein K0/WT
ratio <1 (if the protein is detectable).
The degradation of a polyubiquitination-dependent substrate
is expected to be inhibited upon UbK0 expression. Consequently,
we expect their level to increase. Thus, we require these sub-
strates to (i) have a site K0/WT ratio >1; (ii) have a detectable
MS signal in at least two independent experiments; and (iii) have
a protein K0/WT ratio >1 (if the protein is detectable).
A small fraction (<3%) of proteins were identified as belonging
to the two groups. These proteins were excluded from the survey.
Applying these criteria in both yeast and human cells, we
identified 82 and 220 monoubiquitination-dependent and 416
and 303 polyubiquitination-dependent putative proteasomal
substrates, respectively (Dataset S2). Samples of each group are
presented in Table 1, describing gene names and ubiquitinated
Lys positions. As expected, the polyubiquitination-dependent
substrate group included several previously suggested proteaso-
mal substrates, e.g., Pdc1p, Ole1p, and Eno1p in yeast, and
HIF1A, POLD2, and IER3 in human cells (23, 24).
Candidate Substrate Validation. To validate the results of our algo-
rithm and experimental setup, we monitored the cellular stability
(using cycloheximide chase) of randomly sampled representative
candidate substrates following Ub replacement. As demonstrated
in Fig. 3A, replacing UbWT with UbK0 stabilized Ard1p in yeast and
CDC20 in human cells (polyubiquitination-dependent substrates;
Table 1). In contrast, the predicted monoubiquitination-dependent
substrates, Gre1p in yeast and GOT1 in human cells, remained
unstable. All four substrates were clearly degraded by the 26S pro-
teasome, as they were stabilized following treatment with a protea-
some inhibitor (Fig. 3B). Taken together, these results strongly suggest
that our experimental setup is suitable for the systematic identification
of monoubiquitination-dependent proteasomal substrates.
Physical Characteristics of Protein Substrates Play a Role in Their
Mode of Ubiquitination: (i) Structural Disorder. Evidently, a significant
number of proteins are degraded following monoubiquitination (and
probably also multiple monoubiquitinations) in both yeast and hu-
man cells. This observation challenges the prevailing paradigm of
polyubiquitination being the prerequisite for protein degradation.
Intriguingly, bioinformatics analysis of the data reveals that yeast and
human cells significantly differ in their preferences for using the two
types of signals. In yeast, the ratio of proteins degraded by poly-
ubiquitination vs. monoubiquitination is 5.07 (416/82), whereas in
human cells it is only 1.37 (303/220). Because the identification
method was unbiased, the significant difference in the ratios likely
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Fig. 2. Identification of monoubiquitination- and polyubiquitination-
dependent proteasome substrates. (A) Experimental workflow. See a detailed
description in Results. (B) Ubiquitination sites and ubiquitinated proteins
identified in independent experiments. See Table S1 for experiment names.
(C) The algorithm used for classification to monoubiquitination- and poly-
ubiquitination-dependent substrates.
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points to important differences in the mode of recognition of the
UPS in the two species. Yeast apparently operates muchmore by the
traditional signal, polyubiquitin, whereas in humans monoubiquitination
is used almost as frequently as polyubiquitination to mark proteins
for degradation. The difference may arise from a combination of
factors such as using different sets of conjugating enzymes (E2s and
E3s), different preferences for local sequence and structural features
of substrates, and the recognition elements of the proteasome. Some
of these issues are addressed below.
In previous studies, it has been shown that protein ubiquiti-
nation and degradation are intimately linked with structural
disorder. Intrinsically disordered protein regions lack a well-
defined tertiary structure, yet they fulfill important functional roles
linked with their highly flexible and adaptable structure (25–27).
Structural disorder correlates with all three elements of degra-
dation signals: location of the ubiquitin ligase recognition motif
on substrates, the Lys residue(s) to which ubiquitin is attached,
and a nearby long disordered region (LDR) (a region of at least
30 consecutive disordered residues) that initiates the unfolding of
the substrate engaged with the proteasome (15, 28–30). Structural
disorder may also be required for ubiquitin conjugation itself, in
two different ways. It is repeatedly reported that the mutation of
the Lys residue that is the site of modification does not usually
abrogate sensitivity to UPS degradation (11, 31), because flexi-
bility of the substrate enables multiple modifications on neigh-
boring Lys resides. By a similar logic, the buildup of a polyubiquitin
chain can also benefit from local structural disorder, because it
enables the processive addition of subsequent ubiquitin moieties to
the end of the growing polyubiquitin chain.
To test whether these disorder features may be related to
the use of monoubiquitination vs. polyubiquitination, we tested
whether predicted structural disorder of proteins differs in the
different datasets (Fig. 4A). We found significant differences
between yeast and human proteins: in yeast, the occurrence of
structural disorder does not differ between monoubiquitinated
and polyubiquitinated substrates, whereas in human cells,
structural disorder prevails in polyubiquitinated substrates.
Given that polyubiquitin is a stronger signal, we presume that
Table 1. Putative ubiquitination-mediated proteasomal substrates
Entry Protein name Gene name
Ubiquitination
positions
Ubiquitination
mode/organism
Q00416 Helicase SEN1 SEN1 464 Mono/yeast
P22943 12-kDa heat shock protein HSP12 12, 18, 23, 30, 36,
50, 64, 86, 88, 108
Q08969 Protein GRE1 GRE1 7
Q12734 Transcription factor CSR2 CSR2 670
Q92325 Cullin-associated NEDD8-
dissociated protein 1 homolog
LAG2 7
Q04602 Vacuolar basic amino acid transporter 4 VBA4 368
P36035 Carboxylic acid transporter protein homolog JEN1 607
P01094 Protease A inhibitor 3 PAI3 16, 18, 31, 32, 50
Q12358 α-Ketoglutarate-dependent
sulfonate dioxygenase
JLP1 114 Poly/yeast
P08679 Citrate synthase, peroxisomal CIT2 96, 208, 454
Q05637 Phosphate metabolism protein 6 PHM6 19
P40483 Putative zinc metalloproteinase
YIL108W
YIL108W 5, 348, 524
P07347 N-terminal acetyltransferase A
complex catalytic subunit ARD1
ARD1 191
P00924 Enolase 1 ENO1 195, 409
P06169 Pyruvate decarboxylase isozyme 1 PDC1 8
P21147 Acyl-CoA desaturase 1 OLE1 457
Q92890 Ubiquitin fusion degradation protein
1 homolog
UFD1L 279 Mono/human
Q9BT67 NEDD4 family-interacting protein 1 NDFIP1, N4WBP5,
PSEC0192, PSEC0223
83
Q9P2T1 GMP reductase 2 GMPR2 190
Q92621 Nuclear pore complex protein Nup205 NUP205, C7orf14, KIAA0225 69
Q9H9T3 Elongator complex protein 3 ELP3 338, 392, 517, 544
P17174 Aspartate aminotransferase, cytoplasmic GOT1 97, 99
Q5JVF3 PCI domain-containing protein 2 PCID2, HT004 213
O95302 Peptidyl-prolyl cis-trans isomerase FKBP9 FKBP9, FKBP60, FKBP63 527
Q5JW28 Double-stranded RNA-binding
protein Staufen homolog 1
STAU1 127 Poly/human
P36543 V-type proton ATPase subunit E 1 ATP6V1E1, ATP6E, ATP6E2 10
Q9NWF9 E3 ubiquitin-protein ligase RNF216 RNF216, TRIAD3,
UBCE7IP1, ZIN
487, 584, 773
Q9NS91 E3 ubiquitin-protein ligase RAD18 RAD18, RNF73 115, 376
Q12834 Cell division cycle protein 20 homolog CDC20 136
Q16665 Hypoxia-inducible factor 1α HIF1A, BHLHE78,
MOP1, PASD8
377, 389, 674, 709
P46695 Radiation-inducible immediate-early gene IEX-1 IER3, DIF2, IEX1, PRG1 84
P49005 DNA polymerase δ-subunit 2 POLD2 267
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structural disorder is primarily used for the buildup of the poly-
ubiquitin chain. Because yeast relies more heavily on poly-
ubiquitination, yet its polyubiquitinated substrates do not have
more disorder, it is possible that their E3 ligases differ from
humans in some critical features. These can be their number/
redundancy, structural disorder, or binding heterogeneity, the
structural disorder of which ensures processive addition of
ubiquitin moieties in the ubiquitin chain.
These differences also have to manifest themselves in the
local disorder of the protein chain around the ubiquitinated Lys
residues. In general, the sites of posttranslational modifications
(PTMs) in proteins tend to exhibit local disorder, as studied in
detail for phosphorylation (32) and also ubiquitination (28). In
our entire dataset, the lysines that are the sites of ubiquitination
tend to be locally disordered, but even more importantly, they
show a highly characteristic difference between the two species.
In yeast, monoubiquitination sites, whereas in human cells pol-
yubiquitination sites, are significantly more disordered (Fig. 4B).
Our interpretation, again, is that these differences point to likely
differences in the UPS in the two species. In yeast, poly-
ubiquitination is robust, and it is the rare monoubiquitination
sites that have to be supported by local disorder, probably more
for initiation of degradation than modification (29). In human
cells, the sites of polyubiquitination are significantly more dis-
ordered, probably as much for the processive buildup of the
polyubiquitin chain as for initiation of degradation (as suggested
above). These are genuine differences and do not result from the
natural tendency of lysines to be locally disordered, which, as
disorder-promoting amino acids, tend to be located in disor-
dered regions of proteins (33) (Fig. S3A).
The distinction between the signaling strength and function-
ality of monoubiquitin and polyubiquitin chains in yeast and
human cells is also reflected in characteristic differences in the
proximity of LDRs to Ubsites, which might be the sites of initi-
ation of proteasomal degradation (28–30). The need of such
assistance for monoubiquitination sites in yeast is apparent from
the larger proportion of such sites that are close to an LDR (Fig.
4C), and probably also by a larger proportion of such sites that
are close to the termini of the proteins, which are generally
flexible (Fig. S3B).
Conservation in evolution can be an important indicator of the
functionality of PTM sites. For example, functional phosphory-
lation sites (i.e., were shown to have a functional role by direct or
indirect evidence, e.g., mutagenesis and/or functional assays)
evolve significantly slower than those without evidence for a
functional role (34). Interestingly, Ubsites are significantly more
conserved in human cells than in yeast (Fig. S3C) (these differ-
ences are significant because the phylogenetic coverage of the
respective multiple alignments is comparable). These results
infer that yeast sites are under a significantly lower evolutionary
pressure, which may point to the fact that they are functionally
more promiscuous.
Physical Characteristics of the Proteins Play a Role in Their Mode of
Ubiquitination: (ii) Size of the Protein. In a previous study, we
demonstrated that substrates degraded following conjugation of
a single Ub moiety are usually shorter than 150 aa (15), which
suggests that monoubiquitination is a weaker signal. Consis-
tently, we found in this study a significant enrichment of shorter
proteins among monoubiquitinated substrates in both yeast and
human (Fig. S3D). This difference is not reflected in a prefer-
ence of multiple modifications in longer proteins: there are no
significant differences in the length of substrates that are de-
graded after the attachment of a single vs. multiple mono-
ubiquitin or polyubiquitin chains (Fig. S3E).
Monoubiquitination- and Polyubiquitination-Dependent Substrates
Are Differentially Enriched in Specific Biological Processes. To
characterize the two different modes of ubiquitination in a cel-
lular function perspective, we searched for enriched gene on-
tology (GO) terms, using the GOrilla tool (35, 36). As illustrated
in Fig. 5A, it appears that monoubiquitination-dependent pro-
teasomal substrates are enriched in oxidative stress response and
carbohydrate transport pathways. As presented in Fig. 5B,
molecular-function–specific GO terms were also identified. For
example, monoubiquitination-dependent substrates were found
enriched among ribosomal and proteasomal subunits. Similari-
ties between the monoubiquitinated and polyubiquitinated sub-
strates were also observed, as Ub system components were enriched
in both groups. Interestingly, however, monoubiquitinated substrates
consisted of mostly Ub ligases, E3s (e.g., HERC3, ITCH, XIAP),
whereas polyubiquitinated substrates were enriched with Ub-
conjugating enzymes, E2s (e.g., UBE2J1, UBE2T, and UBE2L6).
Ubiquitination Site Sequence Analysis Reveals Unique Patterns. Pre-
vious studies have demonstrated motifs and sequence patterns
specific for protein posttranslational modifications such as phosphor-
ylation, acetylation, and SUMOylation (29, 30, 37, 38). To identify
Ubsite motifs, we analyzed our data using the Motif-X algorithm (39).
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Fig. 3. Validation of representative candidate substrates degraded by the
proteasome following monoubiquitination and polyubiquitination. (A, Up-
per) MCF7 cells were cotransfected with plasmids coding for GOT1-HA or
CDC20-HA along with plasmids coding for UbWT or UbK0 as indicated.
(Lower) ΔUbUbWT and ΔUbUbK0 yeast cells were transformed with plasmids
coding for Gre1p-HA or Ard1p-HA, and Ub replacement was carried out as
described in Fig. 1. In all experiments, substrate stability was monitored as
described in Experimental Procedures. (B, Upper) MCF7 cells were trans-
fected with either GOT1-HA or CDC20-HA, followed by the treatment with
epoxomicin (2 μM, 24 h) as indicated. (Lower) ΔPDR5 yeast cells (strain
Y12409 from the EUROSCARF collection) were transformed with plasmids
coding for either Ard1p-HA or Gre1p-HA. Strains were treated with cyclo-
heximide (CHX) and bortezomib (100 μM each) as indicated. Samples were
collected at the indicated time points. Cell lysates were analyzed via SDS/
PAGE followed by WB using the indicated antibodies.
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Consistent with previous findings (24), no specific motif was found
when analyzing all identified Ubsites in either yeast or human cells. To
analyze Ubsite amino acid composition, all identified Ubsites were
examined. We constructed an alignment of peptides that are sur-
rounding each modified Lys residue. Residue- and position-specific
amino acid occurrences were calculated and were compared with the
corresponding proteomic occurrence in a lysine-centered peptide. As
depicted in Fig. S4A, ubiquitination sites demonstrated residues-spe-
cific enrichment (e.g., Ala, Gly, Gln) and underrepresentation (e.g.,
Cys, His, Lys, Met, Trp) for both yeast and human cells. Enrichment
of Glu, and to a lesser extent Asp, was specific to yeast sites. Im-
portantly, for several amino acids, the enrichment factor depended on
the proximity to the modified Lys, suggesting that these residues can
affect conjugation mechanisms.
To compare the ubiquitination site composition of mono-
ubiquitination- vs. polyubiquitination-dependent substrates, we
performed the above analysis for each group separately. As shown
in Fig. S4 B and C, each group displays a unique pattern of en-
richment factors, and several differences can be observed between
the patterns of monoubiquitination- and polyubiquitination-
dependent substrates.
Discussion
In this study, we identified 82 yeast and 220 mammalian proteins
that are degraded by the proteasome following monoubiquitination.
These significant numbers point to a much broader phenomenon to
what was considered until recently as an exception. Therefore, it
allows for analysis that sheds light on the mechanisms that underlie
the different modes of ubiquitination. Because we did not use
proteasome inhibitors, it is likely that some low level, rapidly
degrading proteins were below the detection threshold, and there-
fore the numbers are probably larger.
Experimentally, we replaced UbWT with UbK0 in cells to enforce
monoubiquitination. This strategy has been used successfully to
inhibit polyubiquitination-dependent proteasomal degradation (14,
17–19). Other methods to study monoubiquitination have been
reported, such as inhibition of polyubiquitin chain formation by
methylated Ub (40), or detection by Western blotting of specific
substrates that appear to be monoubiquitinated (10). However,
using methylated Ub is limited to cell-free systems, and using en-
dogenous Ub can identify only individual substrates. Therefore,
these methods limit the ability to identify and characterize the
broad population of target substrates degraded by the proteasome
following monoubiquitination and polyubiquitination. Thus, UbWT-
to-UbK0 replacement in cells seemed to be the most suitable
strategy for our objective of carrying out a proteome-wide screen
to identify these two distinct populations.
Notably, although efficient UbK0 expression inhibits poly-
ubiquitination, it may still support the conjugation of several
UbK0 molecules to a protein substrate, resulting in multiple
monoubiquitinations. In our study, we included monoubiquitinated
Fig. 4. Yeast and human substrates demonstrate distinct patterns of structural disorder. (A) Human polyubiquitinated substrates are more disordered than
monoubiquitinated substrates. The distribution of overall disorder content in monoubiquitinated and polyubiquitinated substrates is plotted for yeast
(Upper) and human (Lower). Overall disorder content is the fraction of predicted disordered residues in a given protein sequence. The distribution for the
reference proteome corresponding to each species is shown for comparison. Dotted vertical lines correspond to the average values for the distribution. (B)
Local disorder at the ubiquitination sites is more prominent in yeast monoubiquitination substrates and in human polyubiquitination substrates. The dis-
tribution of local disorder score is plotted for monoubiquitinated and polyubiquitinated sites from yeast (Upper) and human (Lower). The disorder profile for
each sequence is first calculated using IUPred, and then the average disorder score of a 21-residue sequence window centered on each Ubsite is calculated.
The distribution for the reference proteome corresponding to each species is shown for comparison. Dotted vertical lines correspond to the average values for
the distribution. (C) The distance of Ubsites from their nearest LDR (see Experimental Procedures for definition) is plotted for yeast (Upper) and human
(Lower) sites. The averages of the distributions are not shown here for the sake of clarity.
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and multiple-monoubiquitinated substrates in the same group, as
discriminating between the two is complicated experimentally.
Importantly, in our screen, we decided not to use proteasome
inhibitors as a tool to identify substrates that are nevertheless
degraded following Ub replacement; the reason being that, in
human cells infected with adenoviral HA-UbWT, we could not
observe up-regulation of Ub conjugates following treatment with
a proteasome inhibitor (Fig. S5A). It should be noted that the
proteasome in the control cells was active (Fig. S5B), and its
inhibition was efficient (Fig. S5C). This finding is consistent with
partial proteasome inhibition by free Ub chains that are accumu-
lated due to the high level of HA-UbWT (41). Also, the use of
proteasome inhibitors is challenging in yeast cells, as low perme-
ability results in low cellular concentration of the drugs (42). No-
tably, in human cells, it was reported that proteasome inhibitors
impair protein synthesis in a selective manner, thus affecting the
proteome in more than one mode. Therefore, interpretation of
proteomic data of experiments carried out in their presence is not
straightforward (43). Accordingly, we have adapted alternative
classification criteria to identify monoubiquitinated vs. poly-
ubiquitinated proteasomal substrates based on MS analyses of the
proteome and ubiquitome under normal conditions and where only
monoUb is available (Results and Fig. 2B). To confirm our results
and to nevertheless relate them to proteasomal degradation, we
integrated data from previous studies (23, 24, 44) and constructed a
reference list of known ubiquitin–proteasome substrates (Dataset
S3). Compared with this list, our polyubiquitination-dependent
substrates were highly enriched with known proteasomal substrates
(P valueyeast = 6.90 × 10
−23 and P valuehuman = 5.06 × 10
−5, by
hypergeometric test). Furthermore, our monoubiquitination-
dependent candidates were also highly enriched with proteasomal
substrates (P valuehuman = 1.10 × 10
−36). These findings strongly
suggest that our experimental model is faithful and offers a reli-
able method for the identification of UPS substrates. Further-
more, we validated biochemically that several randomly sampled
monoubiquitination and polyubiquitination-dependent candidates
that emerged from the screen do indeed belong to their respective
predicted categories (Fig. 3).
Reportedly, membrane proteins such as receptor tyrosine ki-
nases (RTKs) (45) are subjected to monoubiquitination-dependent
lysosomal degradation. To specifically identify proteasomal sub-
strates in the absence of proteasome inhibitors, plasma membrane
proteins were excluded from our screen.
It is interesting to refer to specific proteins that were identified
in previous studies as targeted by monoubiquitination. For ex-
ample, Syndecan-4 (12) did exhibit site K0/WT ratio <1 (for
Lys105) but was detected in one replicate only. Cks-2 (15) dis-
played protein K0/WT ratio <1 at the protein level but had
conflicting ratios at site level. Other substrates including Pax-3
(13) and α-synuclein (10) could not be detected, probably due to
low abundance in the bone-derived U2OS cells (46). Taken to-
gether, it seems that our results are in agreement with random
previous data but should be further substantiated by experiments
in cells from different tissues.
From the bioinformatics analyses of the substrates, several im-
portant and intriguing conclusions can be drawn. First, in agree-
ment with previous studies in which it was shown that substrates of
up to 150 residues can be degraded following monoubiquitination
(15), we found that the distribution of monoubiquitination-
dependent substrates is shifted toward shorter proteins (Fig. S3D).
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Fig. 5. Analysis of molecular functions and involvement in different cellular processes for monoubiquitination and polyubiquitination-dependent substrates.
Monoubiquitination- and polyubiquitination-dependent substrate groups were analyzed for gene ontology (GO) term enrichment using the GOrilla tool, as
described under Experimental Procedures. Representative proteins are shown for each enriched term, and the full list is shown in Table S2. (A) Biological-
process GO term analysis for yeast substrates. (B) Molecular-function GO term analysis for human substrates.
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Furthermore, a difference between yeast and human is also
apparent when comparing the ratio of monoubiquitination- and
polyubiquitination-dependent substrates. Yeast relies more heavily
on polyubiquitination, whereas human cells use both monoubi-
quitination and polyubiquitination with a similar frequency. This
difference can be interpreted if structural disorder is considered as
shown by our own data (Fig. 4 and Fig. S3), and if we assume that a
single ubiquitin moiety is a weaker signal for degradation than
polyubiquitin. As suggested, local structural disorder is involved in
various steps of the UPS cascade, from recognition motifs of E3
ligases through local disorder of ubiquitination sites to an LDR
initiation site of substrate unfolding (28–30).
We have screened our monoubiquitination-dependent sub-
strates for enriched biological-process–related GO terms and
found a highly significant overrepresentation of genes associated
with carbohydrate transport and oxidative stress response path-
ways (Fig. 5A). Because carbohydrate transporters are plasma
membrane proteins, this finding is consistent with previous
studies that demonstrated membrane receptors down-regulation
via monoubiquitination-mediated endocytosis (47). Notably, as
this pathway results in lysosomal/vacuolar rather than protea-
somal degradation, this finding highlights the challenge in dis-
tinguishing between these two degradation modes using our
experimental system. Oxidative stress was shown to activate
cellular signal transduction cascades, and to result in gene ex-
pression modulation (48). The enrichment of oxidative stress
response proteins in our monoubiquitination-dependent sub-
strates may suggest that they are regulated by a common mon-
oubiquitinating E3 ligase(s). Thus, oxidative stress-mediated
down-regulation of this putative E3 may result in up-regulation
of oxidative stress pathway components and activate the re-
spective cellular response. Consistently, microarray experiments
have shown that the expression of the E3s UBR1 and HUL4, and
the E2s CDC43, RAD6, and UBC11, is decreased following ex-
posure to oxidative stress (49).
UPS components were enriched in both groups (Fig. 5B). This
finding most likely represents the previously reported autoubiquiti-
nation of E2s (50–52) and E3s (53–55). Our findings show that E3s
are preferably classified as monoubiquitination-dependent substrates.
In this study, we have determined the sequence positions of
thousands of ubiquitinated lysines. The unsuccessful attempts to
identify a ubiquitination-site motif in this study and in others (24,
56) reflect site-level promiscuity, which is supported by low
ubiquitination sites conservation across eukaryotic species (56),
and by the flexible selection of the ubiquitinated lysines within a
given substrate (11, 31). Additionally, we used position-specific
analysis of relative amino acid abundance to characterize ubiq-
uitination sites (Fig. S4). This method yields a more thorough
representation of the amino acid composition and reflects both
enrichment and underrepresentation trends. According to the
notion of promiscuity, a ubiquitination site should merely pro-
vide a sterically available e-amino group of a Lys residue. Con-
sistently, we found enrichment of small residues (e.g., Ala and
Gly) and decrease in bulky (e.g., Trp) residues in the proximity of
the ubiquitinated Lys. The depletion of Pro at position −1 also
supports this concept, because Pro disrupts the protein’s sec-
ondary structure and might impair the solvent accessibility of a
following Lys residue.
Experimental Procedures
Adenovirus-Mediated Ub Replacement in Human Cells. For Ub silencing,
U2OSshUb (described in ref. 21) cells were treated with 1 μg/mL tetracycline
for 24 h. Fresh tetracycline and adenoviruses encoding either HA-UbWT or
HA-UbK0 were added, and cells were incubated for additional 24 h.
Ub Replacement in Yeast. The construction of ΔUb strain was described
previously [SUB328 (57)]. Briefly, endogenous Ub genes were deleted and
replaced with a Ub gene expressed under a Gal promoter. To construct
ΔUbUbWT and ΔUbUbK0 strains, ΔUb yeast cells were transformed with pUb39
UbWT and pUb39 UbK0, respectively (both genes are under the Cup1 pro-
moter). To replace the Gal-induced Ub, ΔUbUbWT and ΔUbUbK0 yeast cells
were grown to 1.0 OD600nm in standard Hartwell’s complete medium (HC)
without glucose, supplemented with 2% (wt/vol) galactose and 2% (wt/vol)
raffinose. Cells were then washed in double-distilled water (DDW) to
remove galactose and raffinose, and resuspended in HC medium with glu-
cose and 50 μM CuSO4. Cells were incubated for 16 h at 30 °C, collected by
centrifugation, washed in DDW, and frozen in liquid N2.
Ubiquitination Sites Detection Using GG-Modified Peptide Enrichment. Dried
peptides (SI Experimental Procedures, Sample Preparation for MS) were
resuspended in immunoaffinity purification (IAP) buffer (50 mM Mops/
NaOH, pH 7.2, 10 mM Na2HPO4, and 50 mM NaCl), and cleared by centri-
fugation. Supernatants were adjusted to pH 7.0 with NaOH and incubated
with immobilized anti–K-e-GG antibody (Cell Signaling Technology) at 4 °C
for 3 h. Beads were washed with IAP buffer and then with a wash buffer
(500 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 0.1% octyl glu-
coside, pH 7.4). GG-modified peptides were eluted with 0.2% TFA, desalted
on C18 tips, and eluted in two fractions of 20% and 80% (vol/vol) acetoni-
trile. Peptides were analyzed as described in SI Experimental Procedures,MS.
For additional experimental procedures, see SI Experimental Procedures.
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